What is ZYME's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.63B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ZYME?

P/E (TTM) is n/a and 52-week range is $16.00 to $31.34 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ZYME figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ZYME?

The company profile lists revenue (TTM) near $36M, net income (TTM) near $-14.71B, EPS (TTM) near $-2.01 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Zymeworks Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Middletown, Delaware, US, 71.6M shares outstanding, ISIN US98985Y1082 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Zymeworks Inc

$ZYME

Health Care · Biotechnology

IR Run Scenarios

$25.79

+2.10%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 264 full-time employees. The company went IPO on 2019-06-24. The firm is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.

Employees

243

Website

www.zymeworks.com/

IPO

2019-06-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)